---
title: PK and TAb Assays for Biologics and ADCs | CBS
description: "PK assay development, qualification and validation for antibodies and ADCs: total antibody, conjugated drug and free payload by LBA and LC-MS, per ICH M10."
image: https://www.crystalbiosolutions.com/hubfs/pexels-pavel-danilyuk-8442153.jpg
---

![Crystal Bio Solutions logo](https://www.crystalbiosolutions.com/hs-fs/hubfs/Crystal%20Bio%20Solutions%20logo.webp?width=330&height=150&name=Crystal%20Bio%20Solutions%20logo.webp)

- Bioanalysis & Biomarkers 
    - [All Bioanalysis & Biomarker Services](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [PK Assays for Biologics & ADCs](https://www.crystalbiosolutions.com/services/pk-bioanalysis)
    - [NAb & ADA Immunogenicity Assays](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk)
    - [Receptor Occupancy Assays](https://www.crystalbiosolutions.com/services/receptor-occupancy-assays)
- Biologics CMC Analytical 
    - [All Biologics CMC Analytical Services](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Developability Assessment](https://www.crystalbiosolutions.com/services/biologics-developability-assessment)
    - [Extended Characterization by HRMS](https://www.crystalbiosolutions.com/services/biologics-extended-characterization-hrms)
    - [Biotransformation & In Vivo CQA](https://www.crystalbiosolutions.com/services/biotransformation-in-vivo-cqa)
- [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
- Solutions 
    - [ADC Programs](https://www.crystalbiosolutions.com/antibody-drug-conjugates-adc)
    - [Regulatory Affairs Support](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)

- [Resources](https://www.crystalbiosolutions.com/news-and-events)
- [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
- [About Us](https://www.crystalbiosolutions.com/about-us)
- [Locations](https://www.crystalbiosolutions.com/locations)
- [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Request a Proposal](https://www.crystalbiosolutions.com/contact-us)

![Scientist loading a 96-well plate with a multichannel pipette during bioanalysis sample preparation.](https://www.crystalbiosolutions.com/hs-fs/hubfs/bioanalytical-and-biomarker.webp?width=960&height=640&name=bioanalytical-and-biomarker.webp)

# PK Assays for Biologics and ADCs

Crystal Bio Solutions, part of Crystal Group, develops, validates and runs pharmacokinetic (PK) assays for monoclonal and multispecific antibodies, antibody-drug conjugates (ADCs) and other biologics. We use ligand-binding assays, LC-MS and hybrid immunocapture LC-MS methods, choosing the platform for each analyte. Methods supporting regulated PK and toxicokinetic data are validated following ICH M10, and sample analysis is performed in our GLP- and GCLP-compliant bioanalysis laboratory in Pleasanton, California.

[![Let's talk](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/146565877/interactive-264126601418.png)](https://www.crystalbiosolutions.com/hs/cta/wi/redirect?encryptedPayload=AVxigLLb66c0t%2BEXYEcsJhfvqy7SRj0pVsN8XvHJWZLm8HlLgxArfYivRC0eXY9ka%2F4Jbn05bWN51uAMnFvTswlxvvlPKkZtsjcwIAS9iFK3EkyC6nsSu3rRCzEAkIp2OuPaJEtldwm0XobZX6YX2qF9u7R%2BISPAaYQzGk8wygADeG5ncwWG43fH3Kz7gJy%2BcGy%2Fe28NeYaaPLQ9SJusF%2FrOgoO%2FlZlD&webInteractiveContentId=264126601418&portalId=146565877&hsLang=en)

![CBS orange-blue banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20orange-blue%20banner-1.png?width=2000&height=21&name=CBS%20orange-blue%20banner-1.png "CBS orange-blue banner-1")

Total Antibody (TAb) Assays Quantification of antibody-derived drug, conjugated and unconjugated, for mAbs, bispecifics and ADCs. Assay format and reagents are selected, and potential bias from DAR or soluble target is evaluated during method development. Conjugated Antibody or Conjugated Payload Two different measurements: conjugated antibody (antibody carrying at least one payload, usually by ligand-binding assay) or antibody-conjugated payload (payload concentration, usually by hybrid immunocapture LC-MS/MS). The choice depends on the construct and the question. Free Payload by LC-MS/MS Quantification of unconjugated payload and its metabolites using triple quadrupole LC-MS/MS. Ligand-Binding Assays ELISA, MSD, Gyrolab, Luminex and SP-X platforms for sensitive quantification of large molecules in biological matrices. LC-MS and Hybrid Methods Triple quadrupole LC-MS/MS (SCIEX 7500), including hybrid immunocapture LC-MS/MS, when ligand-binding assays are not suitable or critical reagents are not available. For complex analytes, structural information from the HRMS team at our Natick, Massachusetts laboratory can support method development. Validation and Sample Analysis Method development, validation scoped to the study purpose (ICH M10 for regulated PK and toxicokinetic data), and nonclinical and clinical sample analysis in our Pleasanton, California laboratory, with reports prepared to support regulatory submissions.

![CBS orange banner-1](https://www.crystalbiosolutions.com/hs-fs/hubfs/website-assets/CBS%20orange%20banner-1.png?width=2000&height=24&name=CBS%20orange%20banner-1.png "CBS orange banner-1")

![Scientist working in a bioanalysis laboratory](https://www.crystalbiosolutions.com/hs-fs/hubfs/pexels-pavel-danilyuk-8442153.jpg?width=640&height=480&name=pexels-pavel-danilyuk-8442153.jpg) Multi-Analyte PK Strategy for ADCs ADC exposure is rarely described by one analyte. A common starting point is three analytes, adjusted to the construct and the study:

- **Total antibody**, describing the antibody backbone
- **Conjugated antibody or antibody-conjugated payload** (different measurements), describing the conjugated drug
- **Unconjugated (free) payload**, related to potential off-target toxicity

Diverging profiles among these analytes can be consistent with deconjugation in circulation; confirming the mechanism needs supporting data such as in vivo DAR or biotransformation analysis.

## TAb Assay Development, Qualification and Validation

Total antibody (TAb) assays are a core part of PK data for monoclonal antibodies, bispecifics and ADCs. We develop TAb assays in stages matched to the program:

- **Development:** selection of capture and detection reagents (target protein, anti-idiotype or generic anti-human IgG), assay format and minimum required dilution, with evaluation of potential bias from DAR, soluble target or anti-drug antibodies.
- **Qualification:** fit-for-purpose evaluation of accuracy, precision, selectivity and range for discovery and non-GLP studies.
- **Validation:** full validation following ICH M10 for regulated toxicokinetic and clinical PK data, including stability, dilution linearity, parallelism where relevant and incurred sample reanalysis during sample analysis.

Where possible, the same reagents and format carry forward from nonclinical to clinical studies, which helps keep exposure data comparable; when a method changes, cross-validation is used to bridge the data. For ADCs, TAb results are interpreted together with conjugated-drug and free-payload measurements. Immunogenicity assays that run alongside PK are described on our [NAb and ADA assay](https://www.crystalbiosolutions.com/ada-and-nab-testing-in-biologics-pk-efficacy-and-regulatory-risk?hsLang=en) page.

## Related Services

Bioanalysis & Biomarkers PK, immunogenicity and biomarker assays for biologics and novel modalities. ADC Programs Integrated CMC analytical, bioanalysis and modeling support for ADCs. NAb and ADA Assays Immunogenicity assay development, validation and sample analysis. Receptor Occupancy Assays Flow cytometry RO assays to measure target engagement.

## Frequently Asked Questions

 

### What is a PK assay?

A pharmacokinetic (PK) assay measures drug concentrations in biological samples such as serum or plasma over time. The data describe absorption, distribution and clearance, and support dose selection, safety margins and exposure-response analysis in nonclinical and clinical studies.

 

### What is a total antibody (TAb) assay?

A total antibody assay quantifies antibody-derived drug, conjugated and unconjugated. Whether the result is independent of DAR and of target binding depends on the assay format and reagents, and is shown during method development and validation, particularly when soluble target is present. It is a core PK analyte for ADCs and bispecific antibodies, where it is interpreted alongside conjugated-drug and free-payload measurements.

 

### Which analytes are measured in ADC PK studies?

A common starting point is total antibody (conjugated and unconjugated), conjugated antibody or antibody-conjugated payload, and unconjugated (free) payload; the final set depends on the construct and the study. Conjugated antibody and conjugated payload are different measurements. Together the analytes describe exposure, are consistent with or argue against deconjugation in circulation, and inform potential payload-related toxicity.

 

### When is LC-MS preferred over a ligand-binding assay for PK?

Ligand-binding assays offer high sensitivity for large molecules and are the usual choice for antibodies. LC-MS is preferred when specificity matters more than raw sensitivity, for example for ADC payloads, peptides and oligonucleotides, or when critical reagents for a ligand-binding assay are not available. Hybrid methods combine immunocapture with LC-MS detection.

 

### What does ICH M10 require for PK assay validation?

ICH M10 applies to chromatographic and ligand-binding assays that measure drug and metabolite concentrations for regulatory PK and toxicokinetic data; biomarker assays and exploratory methods are outside its scope. It sets expectations including selectivity, specificity, calibration curve, accuracy, precision, sensitivity, dilution linearity, stability and, for ligand-binding assays, parallelism where relevant. It also covers incurred sample reanalysis and reporting.

 

### Can PK assays be affected by anti-drug antibodies?

Yes. Anti-drug antibodies can bind the drug and interfere with its detection, or change its clearance. PK and immunogenicity assays are therefore designed and interpreted together, and assay format choices consider drug and ADA tolerance.

 

### Where does Crystal Bio Solutions perform PK sample analysis?

PK method development, validation and sample analysis are performed in the CBS GLP- and GCLP-compliant bioanalysis laboratory in Pleasanton, California. ADC characterization and CMC analytical work are performed at our Natick, Massachusetts laboratory.

 

## Related case studies

- [A Generic LC-MS/MS Solution for ADC PK Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-generic-lc-ms/ms-solution-for-adc-pk-bioanalysis?hsLang=en): A generic LC-MS/MS workflow for total antibody and conjugated payload in ADC PK studies.
- [An LC-MS/MS Method for Oligonucleotide PK Bioanalysis](https://www.crystalbiosolutions.com/news-and-events/a-lc-ms/ms-method-for-oligonucleotide-pk-bioanalysis?hsLang=en): An LC-MS/MS method for oligonucleotide quantitation in PK studies.

[See all case studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study?hsLang=en)

Discuss your assay with Dr. Meina Liang, our Chief Scientific Officer

Bring a real PK, immunogenicity, receptor occupancy or biomarker problem to the leader who supervises our bioanalysis projects. One hour at no cost, with a CDA in place first. Our business development team replies within one business day.

[Request a Consultation](https://www.crystalbiosolutions.com/scientific-consultation?hsLang=en)

## Ready to Start a Project?

Tell us about your study. Our business development team replies within one business day.

[Request a Proposal](https://www.crystalbiosolutions.com/contact-us?hsLang=en)

![Crystal Bio Solutions logo (footer)](https://www.crystalbiosolutions.com/hubfs/Logo_CBS-%E7%AB%96%E7%89%88-%E5%8F%8D%E7%99%BD.png)

- [Our Services](https://www.crystalbiosolutions.com) 
    - [Bioanalysis & Biomarkers](https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers)
    - [Biologics CMC Analytical](https://www.crystalbiosolutions.com/characterization-cmc-analytical)
    - [Clinical Pharmacology](https://www.crystalbiosolutions.com/services/clinical-pharmacology)
    - [Regulatory Affairs](https://www.crystalbiosolutions.com/services/regulatory-affairs-biologics-adc-cgt)
    - [Clinical Support](https://www.crystalbiosolutions.com/clinical-research-services)
- [Information](https://www.crystalbiosolutions.com/news-and-events) 
    - [About Us](https://www.crystalbiosolutions.com/about-us)
    - [Quality & Compliance](https://www.crystalbiosolutions.com/quality-and-compliance)
    - [News & Events](https://www.crystalbiosolutions.com/news-and-events)
    - [Case Studies](https://www.crystalbiosolutions.com/news-and-events/tag/case-study)
    - [Scientific Articles](https://www.crystalbiosolutions.com/news-and-events/tag/blog)
    - [Careers](https://www.crystalbiosolutions.com/careers-at-crystal-bio-solutions)
- [Contact](https://www.crystalbiosolutions.com/contact-us) 
    - [Email Us](mailto:cbs_bd@crystalpharmatech.com)
    - [Contact Form](https://www.crystalbiosolutions.com/contact-us)
    - [Our Locations](https://www.crystalbiosolutions.com/locations)
    - [Crystal Group](https://www.crystalbiosolutions.com/about-us#crystal-group) 
          - [Crystal Pharmatech](https://www.crystalpharmatech.com/)
          - [Crystal NAX](https://www.crystalnax.com/)

<https://www.linkedin.com/company/crystal-bio-solutions/> [Follow us on LinkedIn News, events and openings](https://www.linkedin.com/company/crystal-bio-solutions/)

- [Privacy Policy](https://www.crystalbiosolutions.com/policies/privacy-policy)
- [Terms of Service](https://www.crystalbiosolutions.com/policies/terms-of-service)

Copyright © 2026 Crystal Bio Solutions, Inc. All rights reserved.

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#organization",
  "@type" : "Organization",
  "alternateName" : "CBS",
  "contactPoint" : [ {
    "@type" : "ContactPoint",
    "contactType" : "sales",
    "email" : "cbs_bd@crystalpharmatech.com",
    "url" : "https://www.crystalbiosolutions.com/contact-us"
  } ],
  "logo" : "https://www.crystalbiosolutions.com/hs-fs/hubfs/CBS%20VI%20v2/CBS%20Logo.png",
  "name" : "Crystal Bio Solutions",
  "parentOrganization" : {
    "@type" : "Organization",
    "name" : "Crystal Group",
    "url" : "https://www.crystalpharmatech.com/"
  },
  "sameAs" : [ "https://www.linkedin.com/company/crystal-bio-solutions/" ],
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/#website",
  "@type" : "WebSite",
  "inLanguage" : "en",
  "name" : "Crystal Bio Solutions",
  "publisher" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis/#webpage",
  "@type" : "WebPage",
  "about" : {
    "@id" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis/#service"
  },
  "breadcrumb" : {
    "@id" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis/#breadcrumb"
  },
  "description" : "PK bioanalysis for mAbs, bispecifics and ADCs: total antibody, conjugated drug and free payload assays by LBA, LC-MS and hybrid methods, validated per ICH M10.",
  "inLanguage" : "en",
  "isPartOf" : {
    "@id" : "https://www.crystalbiosolutions.com/#website"
  },
  "name" : "PK Assays for Biologics and ADCs | Crystal Bio Solutions",
  "url" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis/#service",
  "@type" : "Service",
  "areaServed" : "Worldwide",
  "description" : "Development, validation (ICH M10 for regulated PK) and sample analysis of pharmacokinetic assays for antibodies, multispecifics and ADCs, including total antibody, conjugated drug and free payload, by LBA, LC-MS and hybrid methods.",
  "hasOfferCatalog" : {
    "@type" : "OfferCatalog",
    "itemListElement" : [ {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Total antibody (TAb) assays"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Conjugated antibody and antibody-conjugated payload assays"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Free payload quantification by LC-MS/MS"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Ligand-binding assays (ELISA, MSD, Gyrolab, Luminex, SP-X)"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "LC-MS and hybrid LBA/LC-MS"
      }
    }, {
      "@type" : "Offer",
      "itemOffered" : {
        "@type" : "Service",
        "name" : "Method validation (ICH M10 where applicable) and sample analysis"
      }
    } ],
    "name" : "PK Assays for Biologics and ADCs"
  },
  "name" : "PK Assays for Biologics and ADCs",
  "provider" : {
    "@id" : "https://www.crystalbiosolutions.com/#organization"
  },
  "url" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis"
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis/#breadcrumb",
  "@type" : "BreadcrumbList",
  "itemListElement" : [ {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/",
    "name" : "Home",
    "position" : 1
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/bioanalysis-and-biomarkers",
    "name" : "Bioanalysis & Biomarkers",
    "position" : 2
  }, {
    "@type" : "ListItem",
    "item" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis",
    "name" : "PK Assays for Biologics and ADCs",
    "position" : 3
  } ]
}
```

```json
{
  "@context" : "https://schema.org",
  "@id" : "https://www.crystalbiosolutions.com/services/pk-bioanalysis/#faq",
  "@type" : "FAQPage",
  "mainEntity" : [ {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A pharmacokinetic (PK) assay measures drug concentrations in biological samples such as serum or plasma over time. The data describe absorption, distribution and clearance, and support dose selection, safety margins and exposure-response analysis in nonclinical and clinical studies."
    },
    "name" : "What is a PK assay?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A total antibody assay quantifies antibody-derived drug, conjugated and unconjugated. Whether the result is independent of DAR and of target binding depends on the assay format and reagents, and is shown during method development and validation, particularly when soluble target is present. It is a core PK analyte for ADCs and bispecific antibodies, where it is interpreted alongside conjugated-drug and free-payload measurements."
    },
    "name" : "What is a total antibody (TAb) assay?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "A common starting point is total antibody (conjugated and unconjugated), conjugated antibody or antibody-conjugated payload, and unconjugated (free) payload; the final set depends on the construct and the study. Conjugated antibody and conjugated payload are different measurements. Together the analytes describe exposure, are consistent with or argue against deconjugation in circulation, and inform potential payload-related toxicity."
    },
    "name" : "Which analytes are measured in ADC PK studies?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Ligand-binding assays offer high sensitivity for large molecules and are the usual choice for antibodies. LC-MS is preferred when specificity matters more than raw sensitivity, for example for ADC payloads, peptides and oligonucleotides, or when critical reagents for a ligand-binding assay are not available. Hybrid methods combine immunocapture with LC-MS detection."
    },
    "name" : "When is LC-MS preferred over a ligand-binding assay for PK?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "ICH M10 applies to chromatographic and ligand-binding assays that measure drug and metabolite concentrations for regulatory PK and toxicokinetic data; biomarker assays and exploratory methods are outside its scope. It sets expectations including selectivity, specificity, calibration curve, accuracy, precision, sensitivity, dilution linearity, stability and, for ligand-binding assays, parallelism where relevant. It also covers incurred sample reanalysis and reporting."
    },
    "name" : "What does ICH M10 require for PK assay validation?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "Yes. Anti-drug antibodies can bind the drug and interfere with its detection, or change its clearance. PK and immunogenicity assays are therefore designed and interpreted together, and assay format choices consider drug and ADA tolerance."
    },
    "name" : "Can PK assays be affected by anti-drug antibodies?"
  }, {
    "@type" : "Question",
    "acceptedAnswer" : {
      "@type" : "Answer",
      "text" : "PK method development, validation and sample analysis are performed in the CBS GLP- and GCLP-compliant bioanalysis laboratory in Pleasanton, California. ADC characterization and CMC analytical work are performed at our Natick, Massachusetts laboratory."
    },
    "name" : "Where does Crystal Bio Solutions perform PK sample analysis?"
  } ]
}
```